Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5521779 | 0.83 | HRH4 (0.43) | TSHRCTSLCTSBCTSKMEN1 | |
| SCHEMBL5527186 | 0.83 | HRH4 (0.43) | TSHRCTSLCTSBCTSKMEN1 | |
| SCHEMBL5513930 | 0.83 | TAAR1 (0.45) | TSHRCTSLCTSBCTSKMEN1 | |
| SCHEMBL5518091 | 0.83 | TAAR1 (0.45) | TSHRCTSLCTSBCTSKMEN1 | |
| SCHEMBL5527189 | 0.83 | HRH4 (0.43) | TSHRCTSLCTSBCTSKMEN1 | |
| SCHEMBL5513936 | 0.83 | TAAR1 (0.45) | TSHRCTSLCTSBCTSKMEN1 | |
| SCHEMBL8285769 | 0.82 | TDP1 (0.51) | TDP1ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL30103447 | 0.81 | TAAR1 (0.45) | TSHRCTSLCTSBCTSKMEN1 | |
| SCHEMBL5722073 | 0.80 | TDP1 (0.60) | TDP1ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL5525141 | 0.80 | TDP1 (0.60) | TDP1ALDH1A1TP53CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1716100-A2 | THERAPEUTIC AMIDE DERIVATIVES | Pfizer, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | TDP1 4329/4885ALDH1A1 1187/4885TP53 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.